Form 4: Sarepta Therapeutics Executive Dallan Murray Reports Stock Transactions

Chief Customer Officer Dallan Murray reports acquisition and disposal of Sarepta Therapeutics stock related to performance stock units.

Summary

• Dallan Murray, Chief Customer Officer of Sarepta Therapeutics, reported transactions involving the company's common stock.
• On June 21, 2024, Murray acquired 6,250 shares of common stock through the vesting of performance stock units (PSUs).
• Also on June 21, 2024, Murray was granted 5,500 performance stock units.
• On June 24, 2024, 2,352 shares were sold by the company at $164.64 to cover tax withholding obligations related to the vesting of PSUs.
• Following these transactions, Murray directly owns 22,023 shares of Sarepta Therapeutics common stock and 11,750 performance stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and related to executive compensation. The vesting of PSUs suggests achievement of performance milestones, which is mildly positive.

Positives

• The vesting of performance stock units indicates the achievement of certain company milestones as determined by the Compensation Committee.

Negatives

• The sale of shares to cover tax obligations reduces Murray's overall holdings, although this is a standard practice.

Risks

• The value of the performance stock units is tied to the company's future performance and the executive's continued service.

Future Outlook

The earned PSUs granted on March 7, 2022 will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are often tied to performance-based compensation plans. These transactions provide insights into executive sentiment and alignment with company goals.

Comparison to Industry Standards

• Executive compensation packages, including performance stock units, are common in the biotechnology industry to incentivize performance and align executive interests with shareholder value.
• Companies like Amgen, Biogen, and Vertex Pharmaceuticals also utilize similar equity-based compensation strategies for their executives.

Stakeholder Impact

• The vesting of PSUs aligns executive compensation with company performance, potentially benefiting shareholders.
• The transactions themselves have a minimal direct impact on other stakeholders.

Key Dates